Physician profile
Lewis E Winans
NPI 1932177086
$287.31
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $38.70 · 2021: $20.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $34.24 | 2019 | |
| Pfizer INC. | $30.86 | 2019 | |
| Glaxosmithkline, LLC. | $26.33 | 2019-2020 | |
| Mannkind Corporation | $25.20 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.07 | 2019-2020 | |
| Nobel Biocare USA | $20.29 | 2021 | |
| Sanofi Pasteur INC. | $17.23 | 2019 | |
| Novo Nordisk INC | $16.67 | 2019 | |
| Amgen INC. | $15.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.57 | 2019 | |
| Opko Pharmaceuticals, LLC | $13.47 | 2019 | |
| Medtronic USA, INC. | $12.81 | 2019 | |
| Bausch Health US, LLC | $12.55 | 2019 | |
| Amarin Pharma, INC. | $11.34 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $10.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Winans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.